Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7785434,maximal plasma concentration (Cmax),"Compared studies between the pharmacokinetics of phenylpropanolamine (PPA) controlled release suspension (CRS) and that of PPA conventional tablet in 10 healthy volunteers showed that the maximal plasma concentration (Cmax), the minimal plasma concentration (Cmin) and the fluctuation index (FI) values were 169.06 +/- 7.76 ng.",[Comparison of multiple dosage bioavailability between phenylpropanolamine controlled release suspension and conventional tablet in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7785434/),ng,169.06,22486,DB00397,Phenylpropanolamine
,9247842,time to peak serum concentration,Tolterodine was rapidly absorbed following oral administration (time to peak serum concentration 0.9 +/- 0.4 h).,Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),h,0.9,23438,DB00397,Phenylpropanolamine
,9247842,absolute bioavailability,"The absolute bioavailability was highly variable, ranging from 10 to 70%.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),%,10 to 70,23439,DB00397,Phenylpropanolamine
,9247842,volume of distribution at steady-state,"The volume of distribution at steady-state ranged from 0.9 to 1.6 l/kg and systemic clearance ranged from 0.23 to 0.52 l/h/kg, which resulted in a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),[l] / [kg],0.9 to 1.6,23440,DB00397,Phenylpropanolamine
,9247842,systemic clearance,"The volume of distribution at steady-state ranged from 0.9 to 1.6 l/kg and systemic clearance ranged from 0.23 to 0.52 l/h/kg, which resulted in a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),[l] / [h·kg],0.23 to 0.52,23441,DB00397,Phenylpropanolamine
,9247842,terminal half-life,"The volume of distribution at steady-state ranged from 0.9 to 1.6 l/kg and systemic clearance ranged from 0.23 to 0.52 l/h/kg, which resulted in a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),h,2-3,23442,DB00397,Phenylpropanolamine
,9247842,excretion,"Following oral administration of (14C)-tolterodine, the excretion of radioactivity into urine and feces was 77 +/- 4.0% and 17 +/- 3.5%, respectively.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),%,77,23443,DB00397,Phenylpropanolamine
,9247842,excretion,"Following oral administration of (14C)-tolterodine, the excretion of radioactivity into urine and feces was 77 +/- 4.0% and 17 +/- 3.5%, respectively.",Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9247842/),%,17,23444,DB00397,Phenylpropanolamine
,10897096,Cmax,"For the reference formulation, Cmax and AUC values were higher for (+)S-chlorpheniramine ((+)S-CPAM) compared to (-)R-chlorpheniramine ((-)R-CPAM) (13.3 vs.",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),,13,34973,DB00397,Phenylpropanolamine
,10897096,Clt/F,"222 ng/ml/h, respectively) while Clt/F and Vd/F were lower (9.8 vs. 17.6 l/h and 321 vs. 627 l, respectively).",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),[l] / [h],9.8,34974,DB00397,Phenylpropanolamine
,10897096,Vd/F,"222 ng/ml/h, respectively) while Clt/F and Vd/F were lower (9.8 vs. 17.6 l/h and 321 vs. 627 l, respectively).",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),l,321,34975,DB00397,Phenylpropanolamine
,10897096,Vd/F,"222 ng/ml/h, respectively) while Clt/F and Vd/F were lower (9.8 vs. 17.6 l/h and 321 vs. 627 l, respectively).",Stereospecific versus nonstereospecific assessments for the bioequivalence of two formulations of racemic chlorpheniramine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10897096/),l,627,34976,DB00397,Phenylpropanolamine
,8930778,oral bioavailability,"Clemastine showed a first-pass reduction in the extent of absorption, with oral bioavailability calculated as 39.2 +/- 12.4%.",The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930778/),%,39.2,35367,DB00397,Phenylpropanolamine
,8930778,volume of distribution,"Extravascular distribution of drug was suggested by the high volume of distribution (799 +/- 315 L) and low Cmax (0.577 +/- 0.252 ng/mL/mg) observed at 4.77 +/- 2.26 hours after administration, and by the biphasic decline in plasma concentration.",The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930778/),l,799,35368,DB00397,Phenylpropanolamine
,8930778,Cmax,"Extravascular distribution of drug was suggested by the high volume of distribution (799 +/- 315 L) and low Cmax (0.577 +/- 0.252 ng/mL/mg) observed at 4.77 +/- 2.26 hours after administration, and by the biphasic decline in plasma concentration.",The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930778/),[ng] / [mg·ml],0.577,35369,DB00397,Phenylpropanolamine
,8930778,terminal elimination half-life (t1/2),The terminal elimination half-life (t1/2) of clemastine was 21.3 +/- 11.6 hours.,The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930778/),h,21.3,35370,DB00397,Phenylpropanolamine
,8917241,terminal elimination half-life,"In children, the mean (+/-SEM) terminal elimination half-life values for pseudoephedrine, 3.1 +/- 0.5 hours, and for phenylpropanolamine, 2.6 +/- 0.6 hours, were significantly shorter than those found by other investigators in adults.",Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917241/),h,3.1,52266,DB00397,Phenylpropanolamine
,8917241,terminal elimination half-life,"In children, the mean (+/-SEM) terminal elimination half-life values for pseudoephedrine, 3.1 +/- 0.5 hours, and for phenylpropanolamine, 2.6 +/- 0.6 hours, were significantly shorter than those found by other investigators in adults.",Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8917241/),h,2.6,52267,DB00397,Phenylpropanolamine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,0.44,53675,DB00397,Phenylpropanolamine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,0.89,53676,DB00397,Phenylpropanolamine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,0.60,53677,DB00397,Phenylpropanolamine
,21352267,urinary excretion,"Mean urinary excretion of 5-HMT following fesoterodine 4 and 8 mg, respectively, was 0.44 and 0.89 mg in EMs and 0.60 and 1.32 mg in PMs.",Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21352267/),mg,1.32,53678,DB00397,Phenylpropanolamine
,7507589,bioavailability,"Both PPA and PDE are readily and completely absorbed, whereas PE, with a bioavailability of only approximately 38%, is subject to gut wall metabolism and is thought to be absorbed erratically.",Pharmacokinetics of oral decongestants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),%,38,59010,DB00397,Phenylpropanolamine
,7507589,apparent volume of distribution,All three drugs are extensively distributed into extravascular sites (apparent volume of distribution between 2.6 and 5.0 L/kg).,Pharmacokinetics of oral decongestants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),[l] / [kg],2.6 and 5.0,59011,DB00397,Phenylpropanolamine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,2.5,59012,DB00397,Phenylpropanolamine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,4,59013,DB00397,Phenylpropanolamine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,6,59014,DB00397,Phenylpropanolamine
,11258043,Bioavailability,Bioavailability varied between 2-20% in rodents and 58-63% in the dog.,"Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,2-20,60401,DB00397,Phenylpropanolamine
,11258043,Bioavailability,Bioavailability varied between 2-20% in rodents and 58-63% in the dog.,"Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,58-63,60402,DB00397,Phenylpropanolamine
less,11258043,half-life,"The elimination of tolterodine from serum was rapid, with a half-life of less than 2 h in all species.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),h,2,60403,DB00397,Phenylpropanolamine
,11258043,clearance,"A very high clearance in the mouse and rat (10-15 l/h.kg), and in the dog (1.4 l/h.kg), indicated additional non-metabolic clearance mechanisms for tolterodine (shown to be attributed to biliary excretion).","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),[l] / [h·kg],10-15,60404,DB00397,Phenylpropanolamine
,11258043,clearance,"A very high clearance in the mouse and rat (10-15 l/h.kg), and in the dog (1.4 l/h.kg), indicated additional non-metabolic clearance mechanisms for tolterodine (shown to be attributed to biliary excretion).","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),[l] / [h·kg],1.4,60405,DB00397,Phenylpropanolamine
,11258043,Urinary excretion,"Urinary excretion of compound-related radioactive substance was around 15%, 45% and 50%, respectively, in the rat, mouse and dog.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,15,60406,DB00397,Phenylpropanolamine
,11258043,Urinary excretion,"Urinary excretion of compound-related radioactive substance was around 15%, 45% and 50%, respectively, in the rat, mouse and dog.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,45,60407,DB00397,Phenylpropanolamine
,11258043,Urinary excretion,"Urinary excretion of compound-related radioactive substance was around 15%, 45% and 50%, respectively, in the rat, mouse and dog.","Pharmacokinetics of tolterodine, a muscarinic receptor antagonist, in mouse, rat and dog. Interspecies relationship comparing with human pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11258043/),%,50,60408,DB00397,Phenylpropanolamine
,1820895,Peak plasma PPA levels,Peak plasma PPA levels were slightly higher for the transdermal patch compared with the tablet formulation (93.6 ng/ml versus 80.10 ng/ml respectively).,In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820895/),[ng] / [ml],93.6,69362,DB00397,Phenylpropanolamine
,1820895,Peak plasma PPA levels,Peak plasma PPA levels were slightly higher for the transdermal patch compared with the tablet formulation (93.6 ng/ml versus 80.10 ng/ml respectively).,In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820895/),[ng] / [ml],80.10,69363,DB00397,Phenylpropanolamine
,577442,lag time,The intestinal absorption started after a lag time of 0.31 h with an absorption constant of 1.75 h-1.,[Biopharmaceutic investigations with D-norpseudoephedrine (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577442/),h,0.31,74976,DB00397,Phenylpropanolamine
,577442,absorption constant,The intestinal absorption started after a lag time of 0.31 h with an absorption constant of 1.75 h-1.,[Biopharmaceutic investigations with D-norpseudoephedrine (author's transl)]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577442/),1/[h],1.75,74977,DB00397,Phenylpropanolamine
,577442,half-life,The following monoexponential decay of the plasma concentration curve had a half-life of 3 h.,[Biopharmaceutic investigations with D-norpseudoephedrine (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577442/),h,3,74978,DB00397,Phenylpropanolamine
,577442,pKa,The dissociation constant of D-norpseudoephedrine was determined (pKa = 8.92) with a non-logarithmic titration method.,[Biopharmaceutic investigations with D-norpseudoephedrine (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577442/),,8.92,74979,DB00397,Phenylpropanolamine
,14531724,elimination half-life,"The elimination half-life of linezolid is 5-7 hours, and twice-daily administration of 400-600 mg provides steady-state concentrations in the therapeutic range.","Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531724/),h,5-7,79676,DB00397,Phenylpropanolamine
,19282207,half-life (T((1/2))),The maximal concentration (C(max)) was reached 2 h after PPA administration (T(max)) and the half-life (T((1/2))) was 4 h.,Combined pharmacokinetic and urodynamic study of the effects of oral administration of phenylpropanolamine in female Beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282207/),h,4,93772,DB00397,Phenylpropanolamine
,2748514,gastric emptying times,"The multiple-unit system emptied from the stomach gradually over a period of about 180 min, when administered after a light breakfast, whereas the single-unit dosage forms had extremely variable gastric emptying times (range, 60 to greater than 570 min).",Correlation of phenylpropanolamine bioavailability with gastrointestinal transit by scintigraphic monitoring of 111In-labeled hydroxypropylmethylcellulose matrices. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748514/),min,60 to greater,95909,DB00397,Phenylpropanolamine
,2265237,AUC,"On Day 1, the mean +/- SEM, AUC, tmax, and Cmax values were 1651 +/- 127 ng x h ml-1, 4.5 +/- 0.26 h and 143 +/- 13.5 ng ml-1, respectively, for the CR caplet and 1716 +/- 90.3 ng x h ml-1, 1.25 +/- 0.08 h and 126 +/- 5.8 ng ml-1 for the solution, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[h·ng] / [ml],1651,103885,DB00397,Phenylpropanolamine
,2265237,tmax,"On Day 1, the mean +/- SEM, AUC, tmax, and Cmax values were 1651 +/- 127 ng x h ml-1, 4.5 +/- 0.26 h and 143 +/- 13.5 ng ml-1, respectively, for the CR caplet and 1716 +/- 90.3 ng x h ml-1, 1.25 +/- 0.08 h and 126 +/- 5.8 ng ml-1 for the solution, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),h,4.5,103886,DB00397,Phenylpropanolamine
,2265237,tmax,"On Day 1, the mean +/- SEM, AUC, tmax, and Cmax values were 1651 +/- 127 ng x h ml-1, 4.5 +/- 0.26 h and 143 +/- 13.5 ng ml-1, respectively, for the CR caplet and 1716 +/- 90.3 ng x h ml-1, 1.25 +/- 0.08 h and 126 +/- 5.8 ng ml-1 for the solution, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[h·ng] / [ml],1716,103887,DB00397,Phenylpropanolamine
,2265237,tmax,"On Day 1, the mean +/- SEM, AUC, tmax, and Cmax values were 1651 +/- 127 ng x h ml-1, 4.5 +/- 0.26 h and 143 +/- 13.5 ng ml-1, respectively, for the CR caplet and 1716 +/- 90.3 ng x h ml-1, 1.25 +/- 0.08 h and 126 +/- 5.8 ng ml-1 for the solution, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),h,1.25,103888,DB00397,Phenylpropanolamine
,2265237,Cmax,"On Day 1, the mean +/- SEM, AUC, tmax, and Cmax values were 1651 +/- 127 ng x h ml-1, 4.5 +/- 0.26 h and 143 +/- 13.5 ng ml-1, respectively, for the CR caplet and 1716 +/- 90.3 ng x h ml-1, 1.25 +/- 0.08 h and 126 +/- 5.8 ng ml-1 for the solution, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[ng] / [ml],143,103889,DB00397,Phenylpropanolamine
,2265237,Cmax,"On Day 1, the mean +/- SEM, AUC, tmax, and Cmax values were 1651 +/- 127 ng x h ml-1, 4.5 +/- 0.26 h and 143 +/- 13.5 ng ml-1, respectively, for the CR caplet and 1716 +/- 90.3 ng x h ml-1, 1.25 +/- 0.08 h and 126 +/- 5.8 ng ml-1 for the solution, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[ng] / [ml],126,103890,DB00397,Phenylpropanolamine
,2265237,AUC,"At steady state (Day 4), the mean +/- SEM, AUC, tmax, and Cmax values were 1832 +/- 101 ng x h ml-1, 4.17 +/- 0.17 h and 151 +/- 6.5 ng ml-1, respectively, for the CR caplet and 2014 +/- 116 ng x h ml-1, 1.33 +/- 0.09 h and 143 +/- 8.7 ng ml-1, respectively, for the solution.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[h·ng] / [ml],1832,103891,DB00397,Phenylpropanolamine
,2265237,tmax,"At steady state (Day 4), the mean +/- SEM, AUC, tmax, and Cmax values were 1832 +/- 101 ng x h ml-1, 4.17 +/- 0.17 h and 151 +/- 6.5 ng ml-1, respectively, for the CR caplet and 2014 +/- 116 ng x h ml-1, 1.33 +/- 0.09 h and 143 +/- 8.7 ng ml-1, respectively, for the solution.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),h,1.33,103892,DB00397,Phenylpropanolamine
,2265237,Cmax,"At steady state (Day 4), the mean +/- SEM, AUC, tmax, and Cmax values were 1832 +/- 101 ng x h ml-1, 4.17 +/- 0.17 h and 151 +/- 6.5 ng ml-1, respectively, for the CR caplet and 2014 +/- 116 ng x h ml-1, 1.33 +/- 0.09 h and 143 +/- 8.7 ng ml-1, respectively, for the solution.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[ng] / [ml],151,103893,DB00397,Phenylpropanolamine
,2265237,Cmax,"At steady state (Day 4), the mean +/- SEM, AUC, tmax, and Cmax values were 1832 +/- 101 ng x h ml-1, 4.17 +/- 0.17 h and 151 +/- 6.5 ng ml-1, respectively, for the CR caplet and 2014 +/- 116 ng x h ml-1, 1.33 +/- 0.09 h and 143 +/- 8.7 ng ml-1, respectively, for the solution.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[ng] / [ml],143,103894,DB00397,Phenylpropanolamine
,2265237,elimination half-life,"The mean +/- SEM, kA, elimination half-life and lag time for PPA HCl from the CR caplet were 0.488 +/- 0.182 ng h ml-1, 5.84 +/- 1.66 h and 0.394 +/- 0.224 h, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),h,5.84,103895,DB00397,Phenylpropanolamine
,2265237,lag time,"The mean +/- SEM, kA, elimination half-life and lag time for PPA HCl from the CR caplet were 0.488 +/- 0.182 ng h ml-1, 5.84 +/- 1.66 h and 0.394 +/- 0.224 h, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),h,0.394,103896,DB00397,Phenylpropanolamine
,2265237,kA,"The mean +/- SEM, kA, elimination half-life and lag time for PPA HCl from the solution were 2.87 +/- 1.51 ng x h ml-1, 3.73 +/- 1.21 h, and 0.325 +/- 0.101 h, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),[h·ng] / [ml],2.87,103897,DB00397,Phenylpropanolamine
,2265237,elimination half-life,"The mean +/- SEM, kA, elimination half-life and lag time for PPA HCl from the solution were 2.87 +/- 1.51 ng x h ml-1, 3.73 +/- 1.21 h, and 0.325 +/- 0.101 h, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),h,3.73,103898,DB00397,Phenylpropanolamine
,2265237,lag time,"The mean +/- SEM, kA, elimination half-life and lag time for PPA HCl from the solution were 2.87 +/- 1.51 ng x h ml-1, 3.73 +/- 1.21 h, and 0.325 +/- 0.101 h, respectively.",Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265237/),h,0.325,103899,DB00397,Phenylpropanolamine
,19371465,peak concentration,"The peak concentration of ephedrine was 3.88 +/- 1.87 mg/mL (mean +/- SD), which was lower than the WADA permitted value (10 mg/mL).",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),[mg] / [ml],3.88,110077,DB00397,Phenylpropanolamine
,19371465,peak concentration,"The peak concentration of ephedrine was 3.88 +/- 1.87 mg/mL (mean +/- SD), which was lower than the WADA permitted value (10 mg/mL).",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),,10,110078,DB00397,Phenylpropanolamine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,5.3,110079,DB00397,Phenylpropanolamine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,4.9,110080,DB00397,Phenylpropanolamine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,4.4,110081,DB00397,Phenylpropanolamine
,19371465,elimination half-lives,"The estimated elimination half-lives of ephedrine, norephedrine, pseudoephedrine, and norpseudoephedrine following administration of this preparation were 5.3 +/- 1.2, 4.9 +/- 0.9, 4.4 +/- 1.0, and 5.4 +/- 1.8 h, respectively.",Elimination of ephedrines in urine following administration of a Sho-seiryu-to preparation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371465/),h,5.4,110082,DB00397,Phenylpropanolamine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,326,111720,DB00397,Phenylpropanolamine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,147,111721,DB00397,Phenylpropanolamine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,342,111722,DB00397,Phenylpropanolamine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,223,111723,DB00397,Phenylpropanolamine
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,260,111724,DB00397,Phenylpropanolamine
,15953705,flow rate,Chromatographic separation was performed on an ODS column at flow rate of 0.2 ml/min.,Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[ml] / [min],0.2,111725,DB00397,Phenylpropanolamine
,15953705,total chromatographic run time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,10.5,111726,DB00397,Phenylpropanolamine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,7.1,111727,DB00397,Phenylpropanolamine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,6.2,111728,DB00397,Phenylpropanolamine
,15953705,retention time,"The total chromatographic run time was 10.5 min with the retention time of 7.1 min and 6.2 min for LOR and DP, respectively, and 2.2 min for both of PES and PPA.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),min,2.2,111729,DB00397,Phenylpropanolamine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],10,111730,DB00397,Phenylpropanolamine
,15953705,LOQ,"The LOQ was 10 pg/ml and 50 pg/ml for LOR and PES, respectively.",Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15953705/),[pg] / [ml],50,111731,DB00397,Phenylpropanolamine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.4,116462,DB00397,Phenylpropanolamine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.24,116463,DB00397,Phenylpropanolamine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.33,116464,DB00397,Phenylpropanolamine
,29128914,retention time,"The retention time of tolterodine, 5-HMT, NDT, and internal standard (IS) were 1.4, 1.24, 1.33, and 1.26 min, respectively.","Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29128914/),min,1.26,116465,DB00397,Phenylpropanolamine
,23489517,maximum cumulative amount permeated in 24 hours (Q24),Permeation parameters were evaluated when maximum cumulative amount permeated in 24 hours (Q24) was 145.71 ± 2.00µg/cm² by CIT4 formulation over control (91.89 ± 2.30µg/cm²).,Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489517/),[μg] / [cm²],145.71,122031,DB00397,Phenylpropanolamine
,23489517,maximum cumulative amount permeated in 24 hours (Q24),Permeation parameters were evaluated when maximum cumulative amount permeated in 24 hours (Q24) was 145.71 ± 2.00µg/cm² by CIT4 formulation over control (91.89 ± 2.30µg/cm²).,Synergistic effect of iontophoresis and chemical enhancers on transdermal permeation of tolterodine tartrate for the treatment of overactive bladder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23489517/),[μg] / [cm²],91.89,122032,DB00397,Phenylpropanolamine
,2341583,t1/2,"The half-life remained relatively constant with an increase in dose (t1/2 = 3.8 to 4.3 hours), as did renal clearance (ClR = 0.41 to 0.44 l/kg/h).",Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341583/),h,3.8 to 4.3,122301,DB00397,Phenylpropanolamine
,2341583,peak serum concentration,"Steady state serum concentrations were significantly higher than single dose concentrations, with the mean peak serum concentration increasing from 113 ng/ml after a single dose to 183 ng/ml at steady state.",Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341583/),[ng] / [ml],113,122302,DB00397,Phenylpropanolamine
,2341583,peak serum concentration,"Steady state serum concentrations were significantly higher than single dose concentrations, with the mean peak serum concentration increasing from 113 ng/ml after a single dose to 183 ng/ml at steady state.",Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341583/),[ng] / [ml],183,122303,DB00397,Phenylpropanolamine
,2341583,time,The time at which these were attained decreased from 1.47 hours after a single dose to 0.73 hours at steady state.,Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341583/),h,1.47,122304,DB00397,Phenylpropanolamine
,2341583,time,The time at which these were attained decreased from 1.47 hours after a single dose to 0.73 hours at steady state.,Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2341583/),h,0.73,122305,DB00397,Phenylpropanolamine
,12848785,half-life,Cathinone was eliminated from the central compartment with a mean half-life of 1.5 +/- 0.8 h.,"Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848785/),h,1.5,128150,DB00397,Phenylpropanolamine
,12848785,half-life,The half-life of cathine was 5.2 +/- 3.4 h.,"Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12848785/),h,5.2,128151,DB00397,Phenylpropanolamine
,19697106,Q(24),The microemulsion system (ME3) containing the highest amount of water (50%) significantly enhanced permeation with Q(24) of 0.746 mg.cm(-2).,Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),[mg] / [(cm)^2],0.746,130983,DB00397,Phenylpropanolamine
,19697106,C(max),"In contrast to oral delivery, a sustained activity was observed over a period of 72 h after transdermal application of this microemulsion to human volunteers with significant lower C(max) (1.06 ng/ml), delayed T(max) (3.17 h) and higher MRT value (147.82 h) (p < 0.05).",Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),[ng] / [ml],1.06,130984,DB00397,Phenylpropanolamine
,19697106,T(max),"In contrast to oral delivery, a sustained activity was observed over a period of 72 h after transdermal application of this microemulsion to human volunteers with significant lower C(max) (1.06 ng/ml), delayed T(max) (3.17 h) and higher MRT value (147.82 h) (p < 0.05).",Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),h,3.17,130985,DB00397,Phenylpropanolamine
,19697106,MRT,"In contrast to oral delivery, a sustained activity was observed over a period of 72 h after transdermal application of this microemulsion to human volunteers with significant lower C(max) (1.06 ng/ml), delayed T(max) (3.17 h) and higher MRT value (147.82 h) (p < 0.05).",Utility of nanosized microemulsion for transdermal delivery of tolterodine tartrate: ex-vivo permeation and in-vivo pharmacokinetic studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19697106/),h,147.82,130986,DB00397,Phenylpropanolamine
,22784220,Peff,"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),[cm] / [s],0.16-44.16 × 10(-4),154149,DB00397,Phenylpropanolamine
,22784220,fraction unbound to plasma proteins (fu),"Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.01-0.99,154150,DB00397,Phenylpropanolamine
,22784220,Saliva/plasma concentrations ratios,"Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability.",Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22784220/),,0.11-13.4,154151,DB00397,Phenylpropanolamine
,27011385,saliva/plasma concentrations ratio,"A high pearsons correlation coefficient of 0.97 between mean saliva and plasma concentrations, and saliva/plasma concentrations ratio of 0.33 were observed.",Saliva versus Plasma Relative Bioavailability of Tolterodine in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27011385/),,0.33,156146,DB00397,Phenylpropanolamine
,15752380,clearance,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.083,156667,DB00397,Phenylpropanolamine
,15752380,clearance,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.038,156668,DB00397,Phenylpropanolamine
,15752380,volume of distribution,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),l,38.6,156669,DB00397,Phenylpropanolamine
,15752380,absorption rate constant,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.064,156670,DB00397,Phenylpropanolamine
,15752380,clearance,"Ephedrine was eliminated mostly renally, with a clearance of 0.34 l min(-1) (CV 11%), and a volume of distribution of 181 l (CV 19%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.34,156671,DB00397,Phenylpropanolamine
,15752380,volume of distribution,"Ephedrine was eliminated mostly renally, with a clearance of 0.34 l min(-1) (CV 11%), and a volume of distribution of 181 l (CV 19%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),l,181,156672,DB00397,Phenylpropanolamine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,15.5,176054,DB00397,Phenylpropanolamine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,5.6,176055,DB00397,Phenylpropanolamine
,12087345,oral clearance,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),[ml] / [min],0.34,176056,DB00397,Phenylpropanolamine
,8531509,relative bioavailability,"The relative bioavailability of the tablet formulation after administration of 16 mg DL-oxyfedrine*HCl, based on the metabolite norephedrine*HCl was for AUC: 85.37% within a 90% confidence interval of 69.29-105.17% and for Cmax: 78.79% within a 90% confidence interval of 59.19-104.90%.",Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531509/),%,85.37,185079,DB00397,Phenylpropanolamine
,8531509,relative bioavailability,"The relative bioavailability of the tablet formulation after administration of 16 mg DL-oxyfedrine*HCl, based on the metabolite norephedrine*HCl was for AUC: 85.37% within a 90% confidence interval of 69.29-105.17% and for Cmax: 78.79% within a 90% confidence interval of 59.19-104.90%.",Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531509/),%,78.79,185080,DB00397,Phenylpropanolamine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],8.0,185266,DB00397,Phenylpropanolamine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],2.1,185267,DB00397,Phenylpropanolamine
,2357862,t[24],"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),,2.4,185268,DB00397,Phenylpropanolamine
,12649305,binding Ki,"The H3-receptor binding Ki values for SCH 79687 were 1.9 and 13 nM in the rat and guinea pig (GP), respectively.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),nM,1.9,191563,DB00397,Phenylpropanolamine
,12649305,binding Ki,"The H3-receptor binding Ki values for SCH 79687 were 1.9 and 13 nM in the rat and guinea pig (GP), respectively.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),nM,13,191564,DB00397,Phenylpropanolamine
greater,12649305,Ki,The Ki values for SCH 79687 at histamine H1 and H2 receptors were greater than 1 microM.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μM,1,191565,DB00397,Phenylpropanolamine
,12649305,pA2,The pA2 value for SCH 79687 in the GP ileum electrical field-stimulated (EFS) contraction was 9.6 +/- 0.3.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,9.6,191566,DB00397,Phenylpropanolamine
,12649305,pKb,Similar H3 antagonist activity was observed in the EFS cryopreserved and fresh tissue isolated human saphenous vein (HSV) assays (pKb = 9.4 +/- 0.3 and 10.1 +/- 0.4).,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,9.4,191567,DB00397,Phenylpropanolamine
,12649305,pKb,Similar H3 antagonist activity was observed in the EFS cryopreserved and fresh tissue isolated human saphenous vein (HSV) assays (pKb = 9.4 +/- 0.3 and 10.1 +/- 0.4).,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,10.1,191568,DB00397,Phenylpropanolamine
,12649305,ED50,SCH 79687 (ED50 = 0.3 mg/kg i.v.) attenuated (R)-alpha-methylhistamine inhibition of sympathetic hypertensive responses in the GP.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),[mg] / [kg],0.3,191569,DB00397,Phenylpropanolamine
greater,12649305,plasma Cmax,"In pharmacokinetic studies, oral dosing with SCH 79687 in the rat (10 mg/kg) and monkey (3 mg/kg) achieved plasma Cmax and area under the curve values greater than 1.5 and 12.1 microg.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μg,1.5,191570,DB00397,Phenylpropanolamine
greater,12649305,area under the curve,"In pharmacokinetic studies, oral dosing with SCH 79687 in the rat (10 mg/kg) and monkey (3 mg/kg) achieved plasma Cmax and area under the curve values greater than 1.5 and 12.1 microg.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μg,12.1,191571,DB00397,Phenylpropanolamine
,25324527,flow rate,"The separation was performed on a Zorbax SB-Aq column (100 mm × 2.1 mm, 3.5 μm) at a flow rate of 0.3 mL/min using acetonitrile-0.1% formic acid aqueous solution as the mobile phase.",Simultaneous quantification and pharmacokinetics of alkaloids in Herba Ephedrae-Radix Aconiti Lateralis extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25324527/),[ml] / [min],0.3,197506,DB00397,Phenylpropanolamine
,9630826,systemic clearance,"The mean systemic clearance of tolterodine was significantly lower (p < 0.001) among poor metabolizers (9.0 +/- 2.1 l/hr) compared with extensive metabolizers (44 +/- 13 L/hr), resulting in a fourfold longer elimination half-life (p < 0.001).",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),[l] / [h],9.0,210214,DB00397,Phenylpropanolamine
,9630826,systemic clearance,"The mean systemic clearance of tolterodine was significantly lower (p < 0.001) among poor metabolizers (9.0 +/- 2.1 l/hr) compared with extensive metabolizers (44 +/- 13 L/hr), resulting in a fourfold longer elimination half-life (p < 0.001).",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),[l] / [h],44,210215,DB00397,Phenylpropanolamine
,9630826,terminal half-life,"The terminal half-life of the 5-hydroxymethyl metabolite (2.9 +/- 0.4 hours) was slightly longer than that of the parent compound (2.3 +/- 0.6 hours) among extensive metabolizers, but the 5-hydroxymethyl metabolite was undetectable in the serum of poor metabolizers.",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),h,2.9,210216,DB00397,Phenylpropanolamine
,9630826,terminal half-life,"The terminal half-life of the 5-hydroxymethyl metabolite (2.9 +/- 0.4 hours) was slightly longer than that of the parent compound (2.3 +/- 0.6 hours) among extensive metabolizers, but the 5-hydroxymethyl metabolite was undetectable in the serum of poor metabolizers.",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),h,2.3,210217,DB00397,Phenylpropanolamine
exceeded,3663885,extraction recovery,PPA extraction recovery exceeded 90 per cent.,"Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663885/),%,90,210360,DB00397,Phenylpropanolamine
,3663885,limit of detection,The limit of detection was 30 ng ml-1 using 0.5 ml plasma and injecting 10 microliter.,"Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663885/),[ng] / [ml],30,210361,DB00397,Phenylpropanolamine
,3663885,terminal elimination half-life,The terminal elimination half-life averaged 3.5 +/- 0.5 h after the i.v. dose.,"Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663885/),h,3.5,210362,DB00397,Phenylpropanolamine
,3663885,bioavailability,Oral absorption from the immediate-release capsule was rapid and bioavailability was 98.2 +/- 6.9 per initial rapid cent.,"Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663885/),1/[cent·initial·rapid],98.2,210363,DB00397,Phenylpropanolamine
,3663885,Oral bioavailability,Oral bioavailability from the controlled release tablet was 93.7 +/- 5.9 per cent.,"Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663885/),%,93.7,210364,DB00397,Phenylpropanolamine
,2608626,Oral bioavailability,Oral bioavailability from the low-crystalline PVA-MA tablet formulation was 78.8 +/- 3.9%.,Polyvinyl alcohol-methyl acrylate copolymers as a sustained-release oral delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2608626/),%,78.8,217887,DB00397,Phenylpropanolamine
,16043426,limit of detection (LOD),The limit of detection (LOD) was 0.05 ng/ml.,High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16043426/),[ng] / [ml],0.05,219426,DB00397,Phenylpropanolamine
,11269570,relative bioavailability,"Based on Cmax and AUC(infinity) ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35-1.71) and 1.53 (1.35-1.72), respectively.",Food increases the bioavailability of tolterodine but not effective exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269570/),,1.49,238499,DB00397,Phenylpropanolamine
,11269570,relative bioavailability,"Based on Cmax and AUC(infinity) ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35-1.71) and 1.53 (1.35-1.72), respectively.",Food increases the bioavailability of tolterodine but not effective exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269570/),,1.53,238500,DB00397,Phenylpropanolamine
,34101369,maximum/minimum concentration,"For the oral formulation, peak-trough fluctuations of tolterodine, 5-HMT, and AM plasma concentrations (AM: mean maximum/minimum concentration, 2580/574 pmol/L = 4.5) were large.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],2580,242075,DB00397,Phenylpropanolamine
,34101369,maximum/minimum concentration,"For the oral formulation, peak-trough fluctuations of tolterodine, 5-HMT, and AM plasma concentrations (AM: mean maximum/minimum concentration, 2580/574 pmol/L = 4.5) were large.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],574,242076,DB00397,Phenylpropanolamine
,34101369,maximum/minimum concentration,"For the oral formulation, peak-trough fluctuations of tolterodine, 5-HMT, and AM plasma concentrations (AM: mean maximum/minimum concentration, 2580/574 pmol/L = 4.5) were large.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],4.5,242077,DB00397,Phenylpropanolamine
,34101369,maximum/minimum concentration,"Intravaginal application led to steadier plasma concentrations (AM, test 3: mean maximum/minimum concentration, 1880/814 pmol/L = 2.3; fluctuation due to initial peak), which is the result of constant releasing rates after ring insertion over the 28-day application period.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],1880,242078,DB00397,Phenylpropanolamine
,34101369,maximum/minimum concentration,"Intravaginal application led to steadier plasma concentrations (AM, test 3: mean maximum/minimum concentration, 1880/814 pmol/L = 2.3; fluctuation due to initial peak), which is the result of constant releasing rates after ring insertion over the 28-day application period.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],814,242079,DB00397,Phenylpropanolamine
,34101369,maximum/minimum concentration,"Intravaginal application led to steadier plasma concentrations (AM, test 3: mean maximum/minimum concentration, 1880/814 pmol/L = 2.3; fluctuation due to initial peak), which is the result of constant releasing rates after ring insertion over the 28-day application period.","Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34101369/),[pM] / [l],2.3,242080,DB00397,Phenylpropanolamine
,24882035,cumulative drug release rate,The measured 24 h cumulative drug release rate (86.02%) was consistent with the predicted value (85.42%) in mice.,Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,86.02,243398,DB00397,Phenylpropanolamine
,24882035,cumulative drug release rate,The measured 24 h cumulative drug release rate (86.02%) was consistent with the predicted value (85.42%) in mice.,Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,85.42,243399,DB00397,Phenylpropanolamine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],15.83,243400,DB00397,Phenylpropanolamine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],18.55,243401,DB00397,Phenylpropanolamine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],37.15,243402,DB00397,Phenylpropanolamine
,24882035,Steady-state flux (J),"Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 μg cm(-2) h(-1), respectively.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[μg] / [(cm)^2·h],81.82,243403,DB00397,Phenylpropanolamine
,24882035,Ea,"Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) results suggested that the hydrogels could impact lipid status in SC, which was consistent with Ea (8.638 kcal/mol) of tolterodine from optimized formulation in rats.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),[kcal] / [mol],8.638,243404,DB00397,Phenylpropanolamine
,24882035,absolute bioavailability,"In the pharmacokinetic studies, sustained-release over 24 h and absolute bioavailability of the hydrogels (24.53%) was higher than tolterodine tablets (15.16%) in rats.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,24.53,243405,DB00397,Phenylpropanolamine
,24882035,absolute bioavailability,"In the pharmacokinetic studies, sustained-release over 24 h and absolute bioavailability of the hydrogels (24.53%) was higher than tolterodine tablets (15.16%) in rats.",Design of transparent film-forming hydrogels of tolterodine and their effects on stratum corneum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24882035/),%,15.16,243406,DB00397,Phenylpropanolamine
,23891744,steady-state speed,Tolterodine permeated at the steady-state speed of 770.19 μg cm(-2)h(-1) and its release coincided with Higuchi Equation.,"Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891744/),[μg] / [(cm)^2],770.19,245212,DB00397,Phenylpropanolamine
,23891744,absolute bioavailability,The absolute bioavailability of tolterodine was 11.47%.,"Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891744/),%,11.47,245213,DB00397,Phenylpropanolamine
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],0.89,246053,DB00397,Phenylpropanolamine
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],0.84,246054,DB00397,Phenylpropanolamine
,19446762,steady-state plasma concentrations,"The mean steady-state plasma concentrations after applying patches without enhancer or with l-menthol and M-OA as enhancers were 0.89, 0.84 and 1.47 microg/mL, respectively.",Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446762/),[μg] / [ml],1.47,246055,DB00397,Phenylpropanolamine
,9850430,Cmax,A significant (p < 0.05) elevation in Cmax (227.45 versus 181.98 micrograms/l) was observed following the drug administration at 22.00 h as compared to 10.00 h.,Pharmacokinetics of a single dose of phenylpropanolamine following oral administration at two different times of the day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850430/),[μg] / [l],227.45,255509,DB00397,Phenylpropanolamine
,9850430,Cmax,A significant (p < 0.05) elevation in Cmax (227.45 versus 181.98 micrograms/l) was observed following the drug administration at 22.00 h as compared to 10.00 h.,Pharmacokinetics of a single dose of phenylpropanolamine following oral administration at two different times of the day. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850430/),[μg] / [l],181.98,255510,DB00397,Phenylpropanolamine
,22126709,steady-state concentration,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),[mg] / [l],0.97,256321,DB00397,Phenylpropanolamine
,22126709,steady-state concentration,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),[mg] / [l],0.49,256322,DB00397,Phenylpropanolamine
,22126709,absolute bioavailability,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),%,27.5,256323,DB00397,Phenylpropanolamine
,22126709,absolute bioavailability,"Comparison of the pharmacokinetic parameters between two types of patches showed that the steady-state concentration of silicone type patch was 2-fold higher than that of acrylic type patch being 0.97 mg/L versus 0.49 mg/L, and the absolute bioavailability was 27.5% for silicone type patch and 6.3% for acrylic type patch, respectively.","Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22126709/),%,6.3,256324,DB00397,Phenylpropanolamine
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],10- 12,263027,DB00397,Phenylpropanolamine
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],4.3-4.7,263028,DB00397,Phenylpropanolamine
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,9.7,263029,DB00397,Phenylpropanolamine
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,15,263030,DB00397,Phenylpropanolamine
,17766197,t1/2,"The t1/2 values of the three drugs in rats were found to be 5.38+/-0.61, 4.49+/-0.53, and 3.70+/-0.19 h for MXL, MTX, and MTR, respectively.","Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766197/),h,5.38,273966,DB00397,Phenylpropanolamine
,17766197,t1/2,"The t1/2 values of the three drugs in rats were found to be 5.38+/-0.61, 4.49+/-0.53, and 3.70+/-0.19 h for MXL, MTX, and MTR, respectively.","Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766197/),h,4.49,273967,DB00397,Phenylpropanolamine
,17766197,t1/2,"The t1/2 values of the three drugs in rats were found to be 5.38+/-0.61, 4.49+/-0.53, and 3.70+/-0.19 h for MXL, MTX, and MTR, respectively.","Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17766197/),h,3.70,273968,DB00397,Phenylpropanolamine
